Trial Profile
Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy Sclnow Biotechnology (Primary) ; Aspirin
- Indications Cerebral infarction
- Focus Adverse reactions
- Sponsors Sclnow Biotechnology
- 11 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 11 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 11 Apr 2023 Planned initiation date changed from 1 Jun 2022 to 1 Dec 2023.